Search

Author/Creator Polli, Anna

2. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Issue 4 (April 2023)

Authors:
Solomon, Benjamin J; Bauer, Todd M; Mok, Tony S K; Liu, Geoffrey; Mazieres, Julien; de Marinis, Filippo; Goto, Yasushi; Kim, Dong-Wan; Wu, Yi-Long; Jassem, Jacek; López, Froylán López; Soo, Ross A; Shaw, Alice T; Polli, Anna; Messina, Rossella; Iadeluca, Laura; Toffalorio, Francesca; Felip, Enriq...
Journal:
Lancet
Issue:
Volume 11:Issue 4(2023)
Page Start:
354
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer with ALK Translocation. (12th February 2020)

Authors:
Patel, Sandip Pravin; Pakkala, Suchita; Pennell, Nathan A.; Reckamp, Karen L.; Lanzalone, Silvana; Polli, Anna; Tarazi, Jamal; Robert‐Vizcarrondo, Francisco
Journal:
Oncologist
Issue:
Volume 25:Number 7(2020)
Page Start:
562
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗